-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
38
1、，
，34，Lumenis（），Lumenis10.
7（69.
5），。
7（69.
5），。
Lumenis。
，Lumenis，、。，。
，Lumenis，、，MOSESTM，。
LumenisTzipiOzer-Armon，Lumenis，，，。
，Lumenis、，。
2、，
，，Lumenis20。，pharmnet.
com.
cn/agent_product/" target="_blank">Lumenis。
com.
cn/agent_product/" target="_blank">Lumenis。
，Lumenis，。
，LumenisMoses——，。
，Meghan Scanlon，MOSESTM ，LithoVue™，。
Meghan Scanlon，20152019，，Lumenis、，。
，、，。
，，2018-2019，201941.
2。
2。
20203，，2019658，8.
8%。
8%。
，，。
At the same time the low level of domestic production, although part of the localization of equipment have entered some medical institutions and beauty institutions, but in our country more than the top three hospitals in laser medical devices still use more imported, mainly due to the laser medical device product certification more difficult, and At present, Chinese residents trust more international laser medical equipment production brands.
In the future, with the acceleration of the localization of the core components of laser medical equipment, such as lasers, the localization rate of laser medical equipment in my country is expected to be greatly improved.
3.
Poco's multiple acquisitions
Poco's multiple acquisitions
Prior to this, Poco had conducted many mergers and acquisitions.
According to reports, on August 19, 2019, Poco announced the completion of the acquisition of BTG, with a purchase amount of US$4.
2 billion.
2 billion.
BTG is a British interventional medicine company that develops minimally invasive surgical products and special medicines for the treatment of vascular diseases and cancer .
BTG has three core businesses, the largest of which is the interventional medicine product portfolio, including tumor interventional therapy technology for the treatment of patients with liver cancer and kidney cancer.
BTG has three core businesses, the largest of which is the interventional medicine product portfolio, including tumor interventional therapy technology for the treatment of patients with liver cancer and kidney cancer.
According to PR Newswire, on September 6, 2018, Poco announced the acquisition of Augmenix for a payment agreement of US$500 million in cash in advance and a payment of no more than US$100 million after the completion of designated sales milestones.
On October 22, 2018, Boston Scientific announced the completion of the acquisition of Augmenix private company.
On October 22, 2018, Boston Scientific announced the completion of the acquisition of Augmenix private company.
Augmenix developed and commercialized the SpaceOAR hydrogel system, which aims to reduce the common side effects of prostate cancer radiotherapy.
The completion of the acquisition means that Poco’s urinary and pelvic floor health product portfolio has completed the third acquisition, further consolidating Poco’s presence in the Field development.
The completion of the acquisition means that Poco’s urinary and pelvic floor health product portfolio has completed the third acquisition, further consolidating Poco’s presence in the Field development.
It is understood that Poco's history began in the late 1960s.
It is a global developer, manufacturer and seller of medical devices, including multiple business segments.
It is a global developer, manufacturer and seller of medical devices, including multiple business segments.
For example, Poco’s endoscopy business develops and manufactures equipment for the diagnosis and treatment of invasive and minimally invasive technologies to diagnose and treat a wide range of gastrointestinal and lung diseases;
Urology and pelvic health business development and manufacture of male and female anatomical structures for the treatment of various urinary and pelvic diseases;
The Heart Rhythm Management (CRM) business develops and manufactures various implantable devices that can monitor the heart and deliver electricity to treat cardiac abnormalities.
In addition, there are electrophysiology business, Neuromodulation business and interventional cardiology business.
On February 3, Poco announced its financial report that the net profit attributable to ordinary shareholders of the parent company for fiscal year 2020 was -173 million US dollars, a year-on-year decrease of 103.
68%; operating income was US$9.
913 billion, a year-on-year decrease of 7.
66%.
68%; operating income was US$9.
913 billion, a year-on-year decrease of 7.
66%.
Medical Network News on March 8
1.
The well-known machinery business was acquired by Poco
The well-known machinery business was acquired by Poco
According to information from China Investment Network, on March 4, Barings Asia Investment Fund and Lumenis (Science Doctor) announced that they had signed an agreement to sell Lumenis’ surgical business to Boston Scientific for US$1.
07 billion (equivalent to approximately RMB 6.
95 billion).
For the company, the final transaction price will be adjusted according to the transaction documents.
07 billion (equivalent to approximately RMB 6.
95 billion).
For the company, the final transaction price will be adjusted according to the transaction documents.
The business involved in this transaction includes Lumenis' laser and fiber optic solutions for minimally invasive surgery in urology and ENT.
Through this transaction, Boston Scientific will acquire all Lumenis surgical businesses, including its world's leading surgical products and solutions, a global business team, and a surgical laser research and development center in Israel.
This transaction may enrich Boston Scientific's urology product line and empower the development strategy of Boston's surgical business.
This transaction may enrich Boston Scientific's urology product line and empower the development strategy of Boston's surgical business.
It is understood that Lumenis is a world-renowned energy medical equipment company with a product line covering the fields of medical aesthetics, surgery and ophthalmology.
Its self-developed patented technology MOSSETM is an important breakthrough in the field of urology and has significant clinical and economic value.
Its self-developed patented technology MOSSETM is an important breakthrough in the field of urology and has significant clinical and economic value.
Lumenis CEO TzipiOzer-Armon said that for Lumenis, this transaction will enable the group to focus more on providing services to the group's medical aesthetics and ophthalmology business customers, and increase scientific research investment to consolidate its market position.
Jiao Yan, managing director of Baring Asia, pointed out that this strategic sale enables Lumenis to focus on the scientific research, commercialization and sales of the medical aesthetics and ophthalmology business, and better grasp the new growth opportunities in the future.
2.
This device was favored by Poco
This device was favored by Poco
According to arterial network information, before this acquisition, Lumenis and Poco had been cooperating for more than 20 years.
Previously, Poco sold Lumenis' urological laser products as an pharmnet.
com.
cn/agent_product/" target="_blank">agent in the United States and Japan .
Previously, Poco sold Lumenis' urological laser products as an pharmnet.
com.
cn/agent_product/" target="_blank">agent in the United States and Japan .
After the acquisition, Boston Scientific plans to sell Lumenis' urology products in global markets, including Europe and the high-growth Chinese market.
It is understood that Poco's most favored Lumenis this time is its Moses laser system, which uses minimally invasive lithotripsy to target oversized kidney stones, locate the stones through a microscope and use lasers to break them up.
According to information from the investment network, Boston Scientific’s senior vice president and president of Urology and Pelvic Health Meghan Scanlon said that MOSSETM laser technology, plus Poco’s LithoVue™ disposable flexible electronic ureteroscope and comprehensive kidney stone management product portfolio, will effectively help Boston Scientifically strengthen the implementation of the stone business strategy.
Meghan Scanlon further pointed out that from 2015 to 2019, Poco has recorded double-digit growth year after year, and looks forward to introducing Lumenis' first-class laser product portfolio, outstanding talents and surgical laser R&D center to further strengthen its strength.
It is understood that laser medical treatment is to use laser technology to research, diagnose and treat diseases, mainly using lasers of different wavelengths to produce biological effects with human organs and tissues to achieve the purpose of treatment.
According to the data of the Foresight Industry Research Institute, combined with the sales revenue of laser equipment in the medical field and the market size of laser equipment, the market size of laser medical equipment in my country from 2018 to 2019 shows a growth trend.
In 2019, the market size of laser medical equipment in my country is 4.
12 billion yuan.
In 2019, the market size of laser medical equipment in my country is 4.
12 billion yuan.
In March 2020, the Chinese Academy of Sciences released an industry report showing that the overall sales revenue of my country's laser equipment market in 2019 reached 65.
8 billion yuan, an increase of 8.
8% year-on-year.
8 billion yuan, an increase of 8.
8% year-on-year.
According to the analysis of the above industry report, the current development of my country's laser medical equipment market is still not as expected, and the market growth rate is still slow.
At the same time the low level of domestic production, although part of the localization of equipment have entered some medical institutions and beauty institutions, but in our country more than the top three hospitals in laser medical devices still use more imported, mainly due to the laser medical device product certification more difficult, and At present, Chinese residents trust more international laser medical equipment production brands.
In the future, with the acceleration of the localization of the core components of laser medical equipment, such as lasers, the localization rate of laser medical equipment in my country is expected to be greatly improved.
3.
Poco's multiple acquisitions
Poco's multiple acquisitions
Prior to this, Poco had conducted many mergers and acquisitions.
According to reports, on August 19, 2019, Poco announced the completion of the acquisition of BTG, with a purchase amount of US$4.
2 billion.
2 billion.
BTG is a British interventional medicine company that develops minimally invasive surgical products and special medicines for the treatment of vascular diseases and cancer .
BTG has three core businesses, the largest of which is the interventional medicine product portfolio, including tumor interventional therapy technology for the treatment of patients with liver cancer and kidney cancer.
BTG has three core businesses, the largest of which is the interventional medicine product portfolio, including tumor interventional therapy technology for the treatment of patients with liver cancer and kidney cancer.
According to PR Newswire, on September 6, 2018, Poco announced the acquisition of Augmenix for a payment agreement of US$500 million in cash in advance and a payment of no more than US$100 million after the completion of designated sales milestones.
On October 22, 2018, Boston Scientific announced the completion of the acquisition of Augmenix private company.
On October 22, 2018, Boston Scientific announced the completion of the acquisition of Augmenix private company.
Augmenix developed and commercialized the SpaceOAR hydrogel system, which aims to reduce the common side effects of prostate cancer radiotherapy.
The completion of the acquisition means that Poco’s urinary and pelvic floor health product portfolio has completed the third acquisition, further consolidating Poco’s presence in the Field development.
The completion of the acquisition means that Poco’s urinary and pelvic floor health product portfolio has completed the third acquisition, further consolidating Poco’s presence in the Field development.
It is understood that Poco's history began in the late 1960s.
It is a global developer, manufacturer and seller of medical devices, including multiple business segments.
It is a global developer, manufacturer and seller of medical devices, including multiple business segments.
For example, Poco’s endoscopy business develops and manufactures equipment for the diagnosis and treatment of invasive and minimally invasive technologies to diagnose and treat a wide range of gastrointestinal and lung diseases;
Urology and pelvic health business development and manufacture of male and female anatomical structures for the treatment of various urinary and pelvic diseases;
The Heart Rhythm Management (CRM) business develops and manufactures various implantable devices that can monitor the heart and deliver electricity to treat cardiac abnormalities.
In addition, there are electrophysiology business, Neuromodulation business and interventional cardiology business.
On February 3, Poco announced its financial report that the net profit attributable to ordinary shareholders of the parent company for fiscal year 2020 was -173 million US dollars, a year-on-year decrease of 103.
68%; operating income was US$9.
913 billion, a year-on-year decrease of 7.
66%.
68%; operating income was US$9.
913 billion, a year-on-year decrease of 7.
66%.
Medical Network News on March 8
1.
The well-known machinery business was acquired by Poco
1. The well-known machinery business was acquired by Poco
The well-known machinery business was acquired by Poco
According to information from China Investment Network, on March 4, Barings Asia Investment Fund and Lumenis (Science Doctor) announced that they had signed an agreement to sell Lumenis’ surgical business to Boston Scientific for US$1.
07 billion (equivalent to approximately RMB 6.
95 billion).
For the company, the final transaction price will be adjusted according to the transaction documents.
07 billion (equivalent to approximately RMB 6.
95 billion).
For the company, the final transaction price will be adjusted according to the transaction documents.
The business involved in this transaction includes Lumenis' laser and fiber optic solutions for minimally invasive surgery in urology and ENT.
Through this transaction, Boston Scientific will acquire all Lumenis surgical businesses, including its world's leading surgical products and solutions, a global business team, and a surgical laser research and development center in Israel.
This transaction may enrich Boston Scientific's urology product line and empower the development strategy of Boston's surgical business.
This transaction may enrich Boston Scientific's urology product line and empower the development strategy of Boston's surgical business.
It is understood that Lumenis is a world-renowned energy medical equipment company with a product line covering the fields of medical aesthetics, surgery and ophthalmology.
Its self-developed patented technology MOSSETM is an important breakthrough in the field of urology and has significant clinical and economic value.
Its self-developed patented technology MOSSETM is an important breakthrough in the field of urology and has significant clinical and economic value.
Lumenis CEO TzipiOzer-Armon said that for Lumenis, this transaction will enable the group to focus more on providing services to the group's medical aesthetics and ophthalmology business customers, and increase scientific research investment to consolidate its market position.
Jiao Yan, managing director of Baring Asia, pointed out that this strategic sale enables Lumenis to focus on the scientific research, commercialization and sales of the medical aesthetics and ophthalmology business, and better grasp the new growth opportunities in the future.
2.
This device was favored by Poco
2. This device was favored by Poco
This device was favored by Poco
According to arterial network information, before this acquisition, Lumenis and Poco had been cooperating for more than 20 years.
Previously, Poco sold Lumenis' urological laser products as an pharmnet.
com.
cn/agent_product/" target="_blank">agent in the United States and Japan .
pharmnet. Previously, Poco sold Lumenis' urological laser products as an pharmnet.
com.
cn/agent_product/" target="_blank">agent in the United States and Japan .
com.
cn/agent_product/" target="_blank">Agentpharmnet.
com.
cn/agent_product/" target="_blank"> Agent Agent
After the acquisition, Boston Scientific plans to sell Lumenis' urology products in global markets, including Europe and the high-growth Chinese market.
It is understood that Poco's most favored Lumenis this time is its Moses laser system, which uses minimally invasive lithotripsy to target oversized kidney stones, locate the stones through a microscope and use lasers to break them up.
According to information from the investment network, Boston Scientific’s senior vice president and president of Urology and Pelvic Health Meghan Scanlon said that MOSSETM laser technology, plus Poco’s LithoVue™ disposable flexible electronic ureteroscope and comprehensive kidney stone management product portfolio, will effectively help Boston Scientifically strengthen the implementation of the stone business strategy.
Meghan Scanlon further pointed out that from 2015 to 2019, Poco has recorded double-digit growth year after year, and looks forward to introducing Lumenis' first-class laser product portfolio, outstanding talents and surgical laser R&D center to further strengthen its strength.
It is understood that laser medical treatment is to use laser technology to research, diagnose and treat diseases, mainly using lasers of different wavelengths to produce biological effects with human organs and tissues to achieve the purpose of treatment.
According to the data of the Foresight Industry Research Institute, combined with the sales revenue of laser equipment in the medical field and the market size of laser equipment, the market size of laser medical equipment in my country from 2018 to 2019 shows a growth trend.
In 2019, the market size of laser medical equipment in my country is 4.
12 billion yuan.
In 2019, the market size of laser medical equipment in my country is 4.
12 billion yuan.
In March 2020, the Chinese Academy of Sciences released an industry report showing that the overall sales revenue of my country's laser equipment market in 2019 reached 65.
8 billion yuan, an increase of 8.
8% year-on-year.
8 billion yuan, an increase of 8.
8% year-on-year.
According to the analysis of the above industry report, the current development of my country's laser medical equipment market is still not as expected, and the market growth rate is still slow.
At the same time the low level of domestic production, although part of the localization of equipment have entered some medical institutions and beauty institutions, but in our country more than the top three hospitals in laser medical devices still use more imported, mainly due to the laser medical device product certification more difficult, and At present, Chinese residents trust more international laser medical equipment production brands.
Hospital hospital hospital medical equipment medical equipment medical equipment In the future, with the acceleration of the localization of the core components of laser medical equipment, such as lasers, the localization rate of laser medical equipment in my country is expected to be greatly improved.
3.
Poco's multiple acquisitions
3. Poco's multiple acquisitions
Poco's multiple acquisitions
Prior to this, Poco had conducted many mergers and acquisitions.
According to reports, on August 19, 2019, Poco announced the completion of the acquisition of BTG, with a purchase amount of US$4.
2 billion.
2 billion.
BTG is a British interventional medicine company that develops minimally invasive surgical products and special medicines for the treatment of vascular diseases and cancer .
BTG has three core businesses, the largest of which is the interventional medicine product portfolio, including tumor interventional therapy technology for the treatment of patients with liver cancer and kidney cancer.
Enterprise enterprise enterprise medicine medicine medicineBTG has three core businesses, the largest of which is the interventional medicine product portfolio, including tumor interventional therapy technology for the treatment of patients with liver cancer and kidney cancer.
According to PR Newswire, on September 6, 2018, Poco announced the acquisition of Augmenix for a payment agreement of US$500 million in cash in advance and a payment of no more than US$100 million after the completion of designated sales milestones.
On October 22, 2018, Boston Scientific announced the completion of the acquisition of Augmenix private company.
On October 22, 2018, Boston Scientific announced the completion of the acquisition of Augmenix private company.
Augmenix developed and commercialized the SpaceOAR hydrogel system, which aims to reduce the common side effects of prostate cancer radiotherapy.
The completion of the acquisition means that Poco’s urinary and pelvic floor health product portfolio has completed the third acquisition, further consolidating Poco’s presence in the Field development.
The completion of the acquisition means that Poco’s urinary and pelvic floor health product portfolio has completed the third acquisition, further consolidating Poco’s presence in the Field development.
It is understood that Poco's history began in the late 1960s.
It is a global developer, manufacturer and seller of medical devices, including multiple business segments.
It is a global developer, manufacturer and seller of medical devices, including multiple business segments.
For example, Poco’s endoscopy business develops and manufactures equipment for the diagnosis and treatment of invasive and minimally invasive technologies to diagnose and treat a wide range of gastrointestinal and lung diseases;
Urology and pelvic health business development and manufacture of male and female anatomical structures for the treatment of various urinary and pelvic diseases;
The Heart Rhythm Management (CRM) business develops and manufactures various implantable devices that can monitor the heart and deliver electricity to treat cardiac abnormalities.
In addition, there are electrophysiology business, Neuromodulation business and interventional cardiology business.
On February 3, Poco announced its financial report that the net profit attributable to ordinary shareholders of the parent company for fiscal year 2020 was -173 million US dollars, a year-on-year decrease of 103.
68%; operating income was US$9.
913 billion, a year-on-year decrease of 7.
66%.
68%; operating income was US$9.
913 billion, a year-on-year decrease of 7.
66%.
